HAVANA, March 26th (The Lancet) Cuba’s long-standing commitment to health has led to a successful COVID-19 pandemic response, but it is threatened by financial and supplier issues.
The Lancet Infectious Diseases went to press, Cuba was due to launch a phase 3 trial of its subunit conjugate vaccine against COVID-19. Soberana-2 is one of four candidate COVID-19 vaccines in development in Cuba.
It is produced by the Finlay Institute in Havana. On the basis of as-yet-unpublished results from early-stage clinical trials, Vicente Verez-Bencomo, director-general of the Finlay Institute, expects the vaccine to show any efficacy in the region of 80–95%. “We are very optimistic”, he said.
If everything goes according to plan, Cuba could start a mass vaccination programme for its 11·2 million citizens sometime in the summer.